Get the Stockscreener App
0.5417
9.87%
-0.0593
Pre-market:
.54
-0.0017
-0.31%
Alx Oncology Holdings Inc stock is traded at $0.5417, with a volume of 1.49M.
It is down -9.87% in the last 24 hours and down -24.47% over the past month.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.
See More
Previous Close:
$0.601
Open:
$0.5254
24h Volume:
1.49M
Relative Volume:
1.58
Market Cap:
$30.23M
Revenue:
-
Net Income/Loss:
$-151.16M
P/E Ratio:
-0.1824
EPS:
-2.97
Net Cash Flow:
$-130.08M
1W Performance:
-1.51%
1M Performance:
-24.47%
6M Performance:
-63.15%
1Y Performance:
-96.79%
1-Day Range:
$0.5254
$0.627
1-Week Range:
$0.5254
$0.66
52-Week Range:
$0.46
$17.82
Alx Oncology Holdings Inc Stock (ALXO) Company Profile
Name
Alx Oncology Holdings Inc
Sector
Industry
Phone
650-466-7125
Address
323 ALLERTON AVENUE, SOUTH SAN FRANCISCO
Compare ALXO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ALXO
Alx Oncology Holdings Inc
|
0.5417 | 30.23M | 0 | -151.16M | -130.08M | -2.97 |
|
VRTX
Vertex Pharmaceuticals Inc
|
493.84 | 122.76B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
602.64 | 61.38B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
614.76 | 36.37B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
251.56 | 30.12B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
244.90 | 24.70B | 3.81B | -644.79M | -669.77M | -6.24 |
Alx Oncology Holdings Inc Stock (ALXO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-06-25 | Upgrade | Jefferies | Hold → Buy |
| Dec-19-24 | Downgrade | Jefferies | Buy → Hold |
| Mar-08-24 | Downgrade | Stifel | Buy → Hold |
| Dec-08-23 | Upgrade | Jefferies | Hold → Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Sep-30-21 | Initiated | Stifel | Buy |
| May-05-21 | Resumed | Credit Suisse | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Apr-06-21 | Initiated | UBS | Buy |
| Feb-10-21 | Initiated | H.C. Wainwright | Buy |
| Aug-11-20 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-11-20 | Initiated | Credit Suisse | Outperform |
| Aug-11-20 | Initiated | Jefferies | Buy |
| Aug-11-20 | Initiated | Piper Sandler | Overweight |
View All
Alx Oncology Holdings Inc Stock (ALXO) Latest News
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World
ALX Oncology faces Nasdaq delisting over price rule - Investing.com Australia
ALX Oncology (ALXO) Stock Dips After Phase 2 Trial Setback - GuruFocus
Evorpacept fails to meet trial endpoints in HNSCC - Investing.com
ALX Oncology faces Nasdaq delisting over price rule By Investing.com - Investing.com South Africa
ALX Oncology Announces Encouraging Final Results from Phase 1 Tr - GuruFocus
Sector Update: Health Care - marketscreener.com
Alx Oncology Holdings Inc: Rising -96.84% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
ALX Oncology (ALXO) Reports Promising Phase 1 Trial Results for Evorpacept in B-Cell Lymphoma | ALXO Stock News - GuruFocus
Evorpacept fails to meet trial endpoints in HNSCC By Investing.com - Investing.com South Africa
ALX Oncology Phase 1/2 Evorpacept Trial to Treat B-cell Non-Hodgkin Lymphoma Shows Anti-tumor Activity - marketscreener.com
ALX Oncology Reports Promising Phase 1 Results for Evorpacept in Combination with Rituximab and Lenalidomide in B-cell Non-Hodgkin Lymphoma at AACR 2025 - Nasdaq
ALX Oncology Announces Encouraging Final Results from Phase 1 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with B-cell Non-Hodgkin Lymphoma - GlobeNewswire
Breakthrough: New Lymphoma Treatment Achieves 83% Complete Response Rate, Outperforming Standard Therapy - Stock Titan
ALX Oncology stock falls on trial setback (ALXO:NASDAQ) - Seeking Alpha
ALX Oncology's Phase 2 Trials In Head & Neck Cancer Fail To Meet Primary Endpoints - Nasdaq
ALX Oncology's Phase 2 Trials of Evorpacept, Keytruda Combination in Head, Neck Cancers Fail to Meet Primary Endpoints - marketscreener.com
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials Evalua - GuruFocus
ALX Oncology (ALXO) Shares Update After Phase 2 Trials Yield Mixed Results | ALXO Stock News - GuruFocus
ALX Oncology Reports ASPEN-03 and ASPEN-04 Phase 2 Trials - GlobeNewswire
ALX Oncology's Evorpacept Falls Short in Dual Phase 2 Head and Neck Cancer TrialsWhat's Next? - Stock Titan
Sei Investments Co. Makes New Investment in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
ALXO stock plunges to 52-week low of $0.48 amid market challenges - Investing.com India
ALXO stock plunges to 52-week low of $0.48 amid market challenges By Investing.com - Investing.com South Africa
ALX Oncology advances new cancer drug into Phase 1 trials By Investing.com - Investing.com South Africa
ALX Oncology Receives IND Clearance from U.S. FDA for ALX2004, a Novel EGFR-targeted Antibody-drug Conjugate - GlobeNewswire
ALX Oncology gets FDA nod to begin trial of ALX2004 (ALXO) - Seeking Alpha
FDA clears ALX Oncology’s IND for ALX-2004 - BioWorld MedTech
Alx Oncology Receives Ind Clearance From U.S. FDA For Alx2004 - marketscreener.com
ALX Oncology advances new cancer drug into Phase 1 trials - Investing.com
Breakthrough Cancer Drug Gets FDA Green Light: ALX2004 Targets Multiple Solid Tumors - Stock Titan
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Average Rating of “Moderate Buy” from Brokerages - Defense World
ALXO stock touches 52-week low at $0.65 amid market challenges - Investing.com Australia
Cantor Fitzgerald Raises Earnings Estimates for ALX Oncology - Defense World
ALXO stock plunges to 52-week low of $0.73 amid market challenges - Investing.com Australia
ALXO stock plunges to 52-week low of $0.73 amid market challenges By Investing.com - Investing.com South Africa
ALX Oncology Holdings (ALXO) Could Find a Support Soon, Here's Why You Should Buy the Stock Now - Yahoo
Why ALX Oncology Holdings Inc. (ALXO) Soared on Thursday - MSN
ALXO stock touches 52-week low at $0.89 amid market challenges - Investing.com Australia
ALXO stock touches 52-week low at $0.89 amid market challenges By Investing.com - Investing.com South Africa
Insider Buying: Rekha Hemrajani Acquires 30,000 Shares of ALX On - GuruFocus.com
ALX Oncology Holdings: Balancing Growth Potential and Uncertainty with a Hold Rating - TipRanks
Stifel Nicolaus Lowers ALX Oncology (NASDAQ:ALXO) Price Target to $1.50 - Defense World
ALX Oncology (NASDAQ:ALXO) Earns “Buy” Rating from HC Wainwright - Defense World
Why the Global Cancer Market Could Surpass $900 Billion-And the Stocks Leading the Charge - The Malaysian Reserve
Alx Oncology Holdings Inc Stock (ALXO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.24%
36.06%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):